Prescription patterns and mineral metabolism abnormalities in the cinacalcet Era: Results from the MBD-5D study

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 9, 2012, Pages 1473-1480

  Fukagawa, Masafumi ^a   Fukuma, Shingo ^b   Onishi, Yoshihiro ^c   Yamaguchi, Takuhiro ^d   Hasegawa, Takeshi ^e   Akizawa, Tadao ^f   Kurokawa, Kiyoshi ^g   Fukuhara, Shunichi ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Institute for Health Outcomes and Process Evaluation Research   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR ACTIVATOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PRESCRIPTION; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CALCIMIMETIC AGENTS; CALCIUM; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 84866083641     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.13081211     Document Type: Article

References (36)

1. St PeterWL, LiQ, Liu J, PerskyM, Nieman K, Arko C, Block GA: Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: 354-360, 2009
2. ArenasMD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nunez C, Devesa R, Carretón MA, Soriano A: Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 22: 1639-1644, 2007
3. Akizawa T, Kido R, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, Fukuhara S, Kurokawa K: Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: Associations with changing practice patterns. Clin J Am Soc Nephrol 6: 2280-2288, 2011
4. Messa P, Macá rio F, YaqoobM, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36-45, 2008
5. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 3: 1718-1725, 2008
6. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidismin hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005
7. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771, 2005
8. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidismin patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
9. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 study group: Cinacalcet (KRN1493) effectively decreases the serumintact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. NephrolDial Transplant 23: 328-335, 2008
10. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL: Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78: 578-589, 2010
11. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793-1800, 2005
12. Evenepoel P: Calcimimetics in chronic kidney disease: Evidence, opportunities and challenges. Kidney Int 74: 265-275, 2008
13. Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, BrinkH, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P: Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron Clin Pract 112: c41-c50, 2009
14. Fukagawa M, Nakanishi S, Kazama JJ: Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl 102: S3-S7, 2006
15. JadoulM, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358-1366, 2006
16. DaneseMD, KimJ, DoanQV, Dylan M, Griffiths R, ChertowGM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47: 149-156, 2006
17. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
18. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
19. Tentori F, Blayney MJ, Albert JM, GillespieBW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
20. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y; Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan: Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12: 49-54, 2008
21. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral bone disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
23. GuidelineWorking Group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12: 514-525, 2008
24. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D: International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 78: 215-223, 2010
25. Fukuhara S, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, Kurokawa K: Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: Rationale and study design. Ther Apher Dial 15: 169-175, 2011
26. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K; MBD-5D Study Group: Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D. Am J Nephrol 33: 427-437, 2011
27. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H: Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18: 759-768, 2003
28. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 4: 643-646, 1973
29. Burton P, Gurrin L, Sly P: Extending the simple linear regression model to account for correlated responses: An introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 17: 1261-1291, 1998
30. Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: An orientation. Am J Epidemiol 157: 364-375, 2003
31. Zeger SL, Liang KY: An overview of methods for the analysis of longitudinal data. Stat Med 11: 1825-1839, 1992
32. Rothman KJ: Epidemiology: An Introduction, New York, Oxford University Press, 2002
33. de Mutsert R, Jager KJ, Zoccali C, Dekker FW: The effect of joint exposures: Examining the presence of interaction. Kidney Int 75: 677-681, 2009
34. Drüeke TB, Ritz E: Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 4: 234-241, 2009
35. Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6: 913-921, 2011
36. Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Hakamada M, Maruyama Y: Influence of the assay for measuring serum albumin on corrected total calcium in chronic hemodialysis patients. Ther Apher Dial 15: 540-546, 2011